These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
287 related items for PubMed ID: 22313330
1. The cost to managed care of managing pulmonary hypertension. Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330 [Abstract] [Full Text] [Related]
2. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Appl Health Econ Health Policy; 2011 Nov 01; 9(6):377-87. PubMed ID: 21888449 [Abstract] [Full Text] [Related]
3. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Appl Health Econ Health Policy; 2011 Sep 01; 9(5):293-303. PubMed ID: 21875160 [Abstract] [Full Text] [Related]
4. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T. J Med Econ; 2010 Sep 01; 13(3):393-402. PubMed ID: 20608882 [Abstract] [Full Text] [Related]
5. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. Copher R, Cerulli A, Watkins A, Laura Monsalvo M. J Med Econ; 2012 Sep 01; 15(5):947-55. PubMed ID: 22554140 [Abstract] [Full Text] [Related]
6. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Curr Med Res Opin; 2011 Sep 01; 27(9):1763-8. PubMed ID: 21793646 [Abstract] [Full Text] [Related]
7. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, Iorga SR. Lupus; 2013 Mar 01; 22(3):268-78. PubMed ID: 23340996 [Abstract] [Full Text] [Related]
8. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Oglesby A, Korves C, Laliberté F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS. Appl Health Econ Health Policy; 2014 Apr 01; 12(2):179-90. PubMed ID: 24573911 [Abstract] [Full Text] [Related]
14. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. Appl Health Econ Health Policy; 2013 Jun 01; 11(3):299-304. PubMed ID: 23580074 [Abstract] [Full Text] [Related]
16. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM. Ann Pharmacother; 2007 Nov 01; 41(11):1761-9. PubMed ID: 17895328 [Abstract] [Full Text] [Related]